SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx) / Rugo, H.S., Im, S., Wright, G.L.S., Escriva-de-Romani, S., Delaurentiis, M., Cortes, J., Bahadur, S.W., Haley, B.B., Oyola, R.H., Riseberg, D.A., Musolino, A., Cardoso, F., Curigliano, G., Kaufman, P.A., Pegram, M.D., Edlich, S., Hong, S., Rock, E.P., Gradishar, W.J.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - 37:15_suppl(2019), pp. 1000-1000. [10.1200/JCO.2019.37.15_suppl.1000]
SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx)
Musolino, AntoninoConceptualization
;
2019-01-01
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
